Sign in or create an account to add this stock to your watchlist.
About SeaSpine (NASDAQ:SPNE)
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPNE
CUSIPN/A
Phone760-727-8399
Debt
Debt-to-Equity RatioN/A
Current Ratio3.65
Quick Ratio1.63
Price-To-Earnings
Trailing P/E Ratio-4.60
Forward P/E Ratio-6.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$131.81 million
Price / Sales1.31
Cash FlowN/A
Price / CashN/A
Book Value$7.40 per share
Price / Book1.60
Profitability
EPS (Most Recent Fiscal Year)($2.58)
Net Income$-32,110,000.00
Net Margins-22.63%
Return on Equity-28.04%
Return on Assets-21.85%
Miscellaneous
Employees327
Outstanding Shares14,540,000
SeaSpine (NASDAQ:SPNE) Frequently Asked Questions
What is SeaSpine's stock symbol?
SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."
How were SeaSpine's earnings last quarter?
SeaSpine Holdings (NASDAQ:SPNE) announced its quarterly earnings data on Thursday, May, 3rd. The medical equipment provider reported ($0.50) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.03. The medical equipment provider earned $33.18 million during the quarter, compared to the consensus estimate of $32.75 million. SeaSpine had a negative return on equity of 28.04% and a negative net margin of 22.63%. View SeaSpine's Earnings History.
When is SeaSpine's next earnings date?
What price target have analysts set for SPNE?
4 equities research analysts have issued 12 month price objectives for SeaSpine's stock. Their predictions range from $15.00 to $22.00. On average, they anticipate SeaSpine's stock price to reach $18.50 in the next twelve months. View Analyst Ratings for SeaSpine.
What are Wall Street analysts saying about SeaSpine stock?
Here are some recent quotes from research analysts about SeaSpine stock:
- 1. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (5/9/2018)
- 2. BTIG Research analysts commented, "From New Products Should Set up FY18 SeaSpine ended FY17 with strength in Orthobiologics driving upside in the quarter. Revenue of $34.0M exceeded BTIG/Consensus original expectations of $33.2M. Guidance was maintained ($135M-$139M) but mgmt. provided further clarity on the cadence of revenue throughout the year. SPNE has been filling out its product portfolio with a variety of unique orthobiologic products which we believe should help to bolster growth. That said, the impact of these products will be felt in 2H18 where growth should approach double digits. In addition with recent added capital from a completed ATM, SPNE has the fire power to increase instrument sets in the field which should help the hardware business as well. Net, net we view the set-up for SPNE as attractive in FY18 as new products improve growth, instrument sets support distributors, and valuation remains reasonable. Gross margins a standout. GMs of 63.3% were well ahead of our expectations and up ~460bps from the year ago quarter. Mgmt. is beginning to get leverage from its Irvine manufacturing facility as newer products comprise a larger portion of rev and can be manufactured at higher margins. FY18 GM guidance was set at 61%- 62%." (3/2/2018)
Who are some of SeaSpine's key competitors?
Some companies that are related to SeaSpine include LeMaitre Vascular (LMAT), SurModics (SRDX), Tandem Diabetes Care (TNDM), Anika Therapeutics (ANIK), Inovio Pharmaceuticals (INO), Accuray (ARAY), Endologix (ELGX), Antares Pharma (ATRS), Utah Medical Products (UTMD), GenMark Diagnostics (GNMK), RenovaCare (RCAR), Westaim (WEDXF), Cytosorbents (CTSO), T2 Biosystems (TTOO) and Pulse Biosciences (PLSE).
Who are SeaSpine's key executives?
SeaSpine's management team includes the folowing people:
- Mr. Keith C. Valentine, Pres, Chief Exec. Officer & Director (Age 50)
- Mr. John J. Bostjancic, Sr. VP & CFO (Age 47)
- Mr. Patrick L. Keran, Gen. Counsel & Corp. Sec. (Age 46)
- Mr. John J. Winge, VP of Sales (Age 51)
- Mr. Tyler P. Lipschultz, Sr. VP of Orthobiologics & Bus. Devel. (Age 51)
Has SeaSpine been receiving favorable news coverage?
News headlines about SPNE stock have been trending somewhat positive on Sunday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SeaSpine earned a news sentiment score of 0.08 on Accern's scale. They also gave news headlines about the medical equipment provider an impact score of 47.92 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are SeaSpine's major shareholders?
SeaSpine's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.53%), BlackRock Inc. (3.06%), Russell Investments Group Ltd. (2.80%), The Manufacturers Life Insurance Company (2.63%) and Northern Trust Corp (0.24%). Company insiders that own SeaSpine stock include John J Bostjancic, Keith Valentine, Michael Fekete, Patrick L Keran and Stuart Essig. View Institutional Ownership Trends for SeaSpine.
Which institutional investors are selling SeaSpine stock?
Which institutional investors are buying SeaSpine stock?
SPNE stock was purchased by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Russell Investments Group Ltd., Dimensional Fund Advisors LP and Northern Trust Corp. Company insiders that have bought SeaSpine stock in the last two years include John J Bostjancic, Keith Valentine, Michael Fekete and Stuart Essig. View Insider Buying and Selling for SeaSpine.
How do I buy shares of SeaSpine?
Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SeaSpine's stock price today?
One share of SPNE stock can currently be purchased for approximately $11.87.
How big of a company is SeaSpine?
SeaSpine has a market capitalization of $172.54 million and generates $131.81 million in revenue each year. The medical equipment provider earns $-32,110,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. SeaSpine employs 327 workers across the globe.
How can I contact SeaSpine?
SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]
MarketBeat Community Rating for SeaSpine (SPNE)
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
SeaSpine (NASDAQ:SPNE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for SeaSpine in the last 12 months. Their average twelve-month price target is $18.50, suggesting that the stock has a possible upside of 55.86%. The high price target for SPNE is $22.00 and the low price target for SPNE is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.50 | $18.50 | $19.00 | $18.50 |
| Price Target Upside: | 55.86% upside | 86.68% upside | 90.76% upside | 81.19% upside |
SeaSpine (NASDAQ:SPNE) Consensus Price Target History
SeaSpine (NASDAQ:SPNE) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
SeaSpine (NASDAQ:SPNE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
SeaSpine (NASDAQ SPNE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.54%
Institutional Ownership Percentage: 38.55%
SeaSpine (NASDAQ SPNE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/10/2017 | Michael Fekete | Director | Buy | 1,490 | $10.25 | $15,272.50 | 32,304 |  |
| 11/8/2017 | Michael Fekete | Director | Buy | 560 | $10.25 | $5,740.00 | 32,304 | |
| 3/15/2017 | Michael Fekete | Director | Buy | 5,100 | $6.65 | $33,915.00 | 15,110 | |
| 3/13/2017 | Patrick L Keran | VP | Sell | 6,315 | $6.66 | $42,057.90 | 16,869 | |
| 3/13/2017 | Stuart Essig | Director | Buy | 50,000 | $6.67 | $333,500.00 | 378,946 | |
| 11/18/2016 | John J Bostjancic | CFO | Buy | 3,900 | $7.02 | $27,378.00 | 22,025 | |
| 11/18/2016 | Keith Valentine | CEO | Buy | 25,000 | $7.00 | $175,000.00 | 101,417 | |
| 5/23/2016 | Keith Valentine | CEO | Buy | 10,000 | $10.16 | $101,600.00 | 70,100 | |
| 5/20/2016 | John J Bostjancic | CFO | Buy | 5,000 | $10.32 | $51,600.00 | 23,072 | |
| 9/2/2015 | John J Bostjancic | CFO | Buy | 2,500 | $14.05 | $35,125.00 | 22,398 | |
| 8/20/2015 | Keith Valentine | CEO | Buy | 65,100 | $15.33 | $997,983.00 | 65,100 | |
(Data available from 1/1/2013 forward)
SeaSpine (NASDAQ SPNE) News Headlines
| Source: |
|
SeaSpine (NASDAQ:SPNE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
SeaSpine (NASDAQ:SPNE) Income Statement, Balance Sheet and Cash Flow Statement
SeaSpine (NASDAQ SPNE) Stock Chart for Sunday, May, 20, 2018
Loading chart…
